Cutaneous castleman's disease responds to anti-interleukin-6 treatment

被引：42
作者：
Ahmed, Bilal
Tschen, Jaime A.
Cohen, Philip R.
Zaki, Mohamed H.
Rady, Peter L.
Tyring, Stephen K.
Corringham, Robert E.
Kurzrock, Razelle
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Phase Program 1, Houston, TX 77030 USA
[2] Univ Houston, Ctr Hlth, Houston, TX 77004 USA
[3] Univ Texas, Houston Med Sch, Dept Dermatol, Houston, TX USA
[4] Univ Texas, Hlth Sci Ctr, Dept Dermatol, Houston, TX USA
[5] Univ Texas, Hlth Sci Ctr, Dept Microbiol, Houston, TX USA
[6] Univ Texas, Hlth Sci Ctr, Dept Mol Genet, Houston, TX USA
[7] Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA
[8] Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA
[9] St Joseph Dermpath, Bellaire, TX USA
[10] Centocor R&D Inc, Clin Hematol & Oncol, Horsham, PA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 09期
关键词：
D O I：
10.1158/1535-7163.MCT-07-0256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Castleman's disease is uncommon, and cutaneous involvement is even rarer. We report a 42-year-old Asian woman with the multicentric plasma cell variant of Castleman's disease limited to her skin. The literature suggests that Castleman's disease is driven by interleukin-6 (IL-6). Based on these data, we hypothesized that suppression of IL-6 would have a salutary effect. Therefore, our patient was treated with CNT0328, a chimeric murine anti-human IL-6 antibody. She has shown a remarkable, ongoing response to this treatment, with almost complete clearing of her skin lesions after six doses.
引用
收藏
页码：2386 / 2390
页数：5
相关论文
共 28 条
[11]  
Kaneda M, 1996, CLIN EXP DERMATOL, V21, P360
[12]   Multicentric plasma cell variant of Castleman's disease with cutaneous involvement [J].
Klein, WM ;
Rencic, A ;
Munshi, NC ;
Nousari, CH .
JOURNAL OF CUTANEOUS PATHOLOGY, 2004, 31 (06) :448-452
[13]   SYSTEMIC AND CUTANEOUS PLASMACYTOSIS WITH MULTIPLE SKIN-LESIONS AND POLYCLONAL HYPERGAMMAGLOBULINEMIA - SIGNIFICANT SERUM INTERLEUKIN-6 LEVELS [J].
KODAMA, A ;
TANI, M ;
HORI, K ;
TOZUKA, T ;
MATSUI, T ;
ITO, M ;
NAKAO, S ;
FUJITA, T ;
KOBAYASHI, H .
BRITISH JOURNAL OF DERMATOLOGY, 1992, 127 (01) :49-53
[14]   SKIN INVOLVEMENT IN GIANT LYMPH-NODE HYPERPLASIA (CASTLEMANS DISEASE) [J].
KUBOTA, Y ;
NOTO, S ;
TAKAKUWA, T ;
TADOKORO, M ;
MIZOGUCHI, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 29 (05) :778-780
[15]   Cytokine deregulation in cancer [J].
Kurzrock, R .
BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (9-10) :543-547
[16]  
LEGERRAVET MB, 1991, BLOOD, V78, P2923
[17]   Cutaneous plasmacytosis associated with lung and anal carcinomas [J].
Martín, JM ;
Calduch, L ;
Monteagudo, C ;
Molina, I ;
Ramón, D ;
Alonso, V ;
Jordá, E .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, 20 (04) :428-431
[18]   Treatment of facial lesion of cutaneous plasmacytosis with tacrolimus ointment [J].
Miura, H ;
Itami, S ;
Yoshikawa, K .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (06) :1195-1196
[19]   Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease [J].
Nishimoto, N ;
Kanakura, Y ;
Aozasa, K ;
Johkoh, T ;
Nakamura, M ;
Nakano, S ;
Nakano, N ;
Ikeda, Y ;
Sasaki, T ;
Nishioka, K ;
Hara, M ;
Taguchi, H ;
Kimura, Y ;
Kato, Y ;
Asaoku, H ;
Kumagai, S ;
Kodama, F ;
Nakahara, H ;
Hagihara, K ;
Yoshizaki, K ;
Kishimoto, T .
BLOOD, 2005, 106 (08) :2627-2632
[20]   Is cutaneous plasmacytosis a distinct clinical entity? [J].
Shimizu, S ;
Tanaka, M ;
Shimizu, H ;
HanYaku, H .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 36 (05) :876-880
123